Is the Turkish version of Abatacept the same as the domestic version?

The Turkish version of Abatacept (Abatacept) was developed by the U.S. pharmaceutical company Bristol-Myers Squibb Holdings and was licensed in the United States for export to Turkey. In it was approved by the U.S. Food and Drug Administration (FDA) in 2005. The abatacept available in China is an imported drug and is developed by the same company. It belongs to the same drug and has the same ingredients. There may be differences in its prices.

Abatacept, whose trade name is Orencia, is a drug that treats autoimmune diseases such as rheumatoid arthritis by interfering with the immune activity of T cells. It is a modified antibody used to treat rheumatoid arthritis that is insufficiently responsive to anti-TNFα therapy. Abataceptis a fusion protein consisting of the Fc region of immunoglobulinIgG1 fused to the extracellular domain of CTLA-4. In order to activate T cells and generate an immune response, antigen-presenting cells must present two signals to the T cells. As a second-line drug to treat adults with moderate to severe rheumatoid arthritis (RA), and as a first-line drug for patients with severe and rapidly progressive RA, it is also used to treat psoriatic arthritis and juvenile idiopathic arthritis.

The original abatacept drug on the domestic market has not yet entered the scope of medical insurance through the relevant policies of the National Medical Insurance Bureau. It is a strictly controlled drug, and its purchase channels are restricted. It must be used by doctors or medical staff. It is a prefilled syringe with specifications of 125mg (0.95ml)*4. The price per box may be more than 6,000 yuan. The price of each box of the Turkish version of abatacept original drug sold overseas may be more than more than 3,000 yuan, and the price of each box of the European version may be more than 10,000 yuan (the price may fluctuate due to exchange rates).